



Raymond De Vré, new Chief Executive Officer from 1 April 2021

Feb 16, 2021 16:47 CET

PolyPeptide Group appoints Raymond De Vré as new Chief Executive Officer

PolyPeptide Group, a global leader in peptide manufacturing and development, today announced the appointment of Dr. Raymond De Vré as its new Chief Executive Officer. He will succeed Jane Salik who has decided to concentrate on her role on the Board of Directors after 15 very successful years as CEO.

Raymond De Vré will join PolyPeptide Group as CEO elect on 1 April 2021 and will work alongside Jane Salik during a transition period prior to taking

up his role as CEO over the course of the summer. Jane Salik will remain a member of the Executive Committee until the summer of 2021, after which she will continue to focus on her role on the Board of Directors.

Raymond De Vré joins from Dr. Reddy's Laboratories, a leading multinational pharmaceutical company based in India, where he is a member of the Management Council and Global Head of Biologics. Over the past 8 years, he has helped grow the biologics business by expanding it internationally, increasing the manufacturing capacity multi-fold and building a robust product pipeline in oncology and immunology. Prior to this, Raymond De Vré spent 15 years with McKinsey & Company, where he was a Partner advising pharmaceutical, biotech and specialty chemical companies in Europe, the US and India on M&A, growth strategies and operational improvements. He is a Belgian national and holds a master's degree in engineering from Université Libre de Bruxelles (ULB) as well as a PhD in applied physics from Stanford University.

Jane Salik has been with PolyPeptide Group since its incorporation as an independent company in 1996 and has more than quadrupled peptide sales and profits since 2006, when she became CEO. She has been responsible for PolyPeptide Group's expansion into new geographies across facilities, and has established a culture of innovation and execution of best practice.

Commenting on the changes, PolyPeptide Group Chairman, Jeffrey Hobbs, said:

"The Board is delighted to have appointed Dr. Raymond De Vré to the PolyPeptide Group as our next CEO. With more than two decades of relevant experience in the industry, Dr. Raymond De Vré is a respected leader in the life sciences community, bringing skills and expertise which will make significant contributions to our continued long-term growth.

On behalf of the entire PolyPeptide Group, I would like to thank Jane for her role in PolyPeptide Group's growth during her outstanding tenure with the company. Her insights and leadership have guided us through a period of significant growth and I'm pleased that we will continue to benefit from her expertise as a member of the Board of Directors."

Dr. Raymond De Vré, incoming Chief Executive Officer, added:

"I am proud to join a company and management team with such exceptional industry knowledge, strong customer focus, unique culture, and track record

of success. I am looking forward to building on these many successes to keep growing the PolyPeptide Group business in the years to come, capturing opportunities driven by innovation in the pharmaceutical and biotech industry.”

Contact

PolyPeptide Group
Limhamnsvägen 108
PO Box 30089
200 61 Limhamn, Sweden
mediateam@polypeptide.com

About PolyPeptide Group

PolyPeptide Group is a privately-held Contract Development & Manufacturing Organization (CDMO) which focuses primarily on proprietary and generic GMP-grade peptides for the diagnostic, cosmetic, pharmaceutical and biotechnological market. The group has manufacturing facilities in Belgium, Sweden, France, India and two sites in the USA. As a multinational company with more than 950 employees worldwide, its diversity brings breadth and depth of knowledge and experience to the group. PolyPeptide Group has grown by selective acquisition of existing expertise, culminating in its position today as a leader in peptide manufacturing.

For more information, visit www.polypeptide.com

PolyPeptide Group is a privately-held Contract Development & Manufacturing Organization (CDMO) which focuses primarily on proprietary and generic GMP-grade peptides for the diagnostic, cosmetic, pharmaceutical and biotechnological market. The group has manufacturing facilities in Belgium, Sweden, France, India and two sites in the USA. As a multinational company with more than 950 employees worldwide, its diversity brings breadth and depth of knowledge and experience to the group. PolyPeptide Group has grown by selective acquisition of existing expertise, culminating in its position today as a leader in peptide manufacturing.